DelveInsight's “Obesity Market Insights, Epidemiology and Market Forecast–2034” report delivers an in-depth understanding of obesity, historical and forecasted epidemiology as well as the obesity market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the Obesity Market with DelveInsight's In-Depth Report @ Obesity Market Size
Key Takeaways from the Obesity Market Report
- In November 2024:- Carmot Therapeutics Inc.- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese with Type 2 Diabetes Mellitus. This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
- In November 2024:- Eli Lilly and Company- A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity. The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
- As per DelveInsight's estimates, the United States accounted for the highest number of total prevalent cases of Obesity among the 7 MM in 2023.
- DelveInsight’s consultant estimates that adult patients constituted the maximum number of cases of obesity patients seeking help in 2023.
- According to the findings, treatment rate for children was found to be less than that of adults across countries.
- Among EU4 and the UK, the highest number of treated cases of obesity in adults was observed in the United Kingdom in 2023, which is followed by Germany.
- The leading Obesity Companies such as Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others
- Promising Obesity Therapies such as IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others
Stay ahead in the Obesity Therapeutics Market with DelveInsight’s Strategic Report @ Obesity Market Outlook
Obesity Epidemiology Segmentation in the 7MM
- Total Prevalence of Obesity
- Prevalent Cases of Obesity by severity
- Gender-specific Prevalence of Obesity
- Diagnosed Cases of Episodic and Chronic Obesity
Download the report to understand which factors are driving Obesity epidemiology trends @ Obesity Prevalence
Marketed Obesity Drugs
- IMCIVREE (setmelanotide): Rhythm Pharmaceuticals
Imcivree is a melanocortin 4 (MC4) receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity. In November 2020, Rhythm Pharmaceuticals announced the US FDA approval of Imcivree as the first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1, or LEPR deficiency. Earlier, in May 2017, FDA expanded the Breakthrough Therapy Designation to disorders involving genetic defects upstream of the melanocortin-4 receptor in the leptin-melanocortin pathway.
- ZEPBOUND (tirzepatide): Eli Lilly and Company
Tirzepatide is a once-weekly glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. In November 2023, the US FDA approved Eli Lilly and Company's ZEPBOUND (tirzepatide) injection, the first obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors. ZEPBOUND is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, Type II diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off.
Emerging Obesity Drugs
- Semaglutide oral: Novo Nordisk
Oral semaglutide is approved as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes in the US, EU and Japan under the trade name, RYBELSUS. It is an oral GLP-1 RA, an analogue of the naturally occurring hormone GLP-1. Currently, the company is developing the candidate for obesity. The candidate is being evaluated in various Phase III trials (OASIS 1, OASIS 2, OASIS 3 and OASIS 4) to assess the safety and efficacy of the drug in subjects with overweight or obesity.
- Survodutide (BI 456906): Boehringer Ingelhium
Survodutide (BI 456906) is a GCGR/GLP1 dual agonist being developed by Boehringer Ingelhium. GLP1 agonism is expected to lower body weight and provide glucose control. Both receptors are critical to controlling metabolic functions. The compound leverages the known effects of the natural gut hormone oxyntomodulin, which has been shown to decrease food intake and increase energy expenditure in humans as well as the established effects of GLP1 agonism on both glucose control and body weight. The dual agonist BI 456906 has potential as a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments.
Get In-Depth Knowledge on Obesity Market Trends and Forecasts with DelveInsight @ Obesity Treatment Market
Scope of the Obesity Market Report
- Coverage- 7MM
- Obesity Companies- Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others
- Obesity Therapies- IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others.
- Obesity Therapeutic Assessment: Obesity Current marketed and Obesity Emerging Therapies
- Obesity Market Dynamics: Obesity Market drivers and Obesity Market Barriers
Unlock Strategic Insights with DelveInsight’s Comprehensive Obesity Market Report @ Obesity Market Drivers and Barriers
Table of Contents
1. Key Insights
2. Report Introduction
3. Obesity Market Overview at a Glance
4. Executive Summary
5. Key Events
6. Epidemiology and Market Methodology
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Japan Epidemiology Scenario
10. Patient Journey
11. Marketed Therapies
12. Emerging Therapies
13. Obesity Market: The 7MM Analysis
14. Obesity Market Access and Reimbursement
15. KOL Views
16. SWOT Analysis
17. Unmet Needs
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage
